Fulcrum expands board to 9, elects Colin Hill; stockholders elect directors, ratify auditor

Fulcrum Therapeutics, Inc.

Board expanded from 8 to 9; Colin Hill elected Class I director, term expiring at 2026 annual meeting.
Hill received automatic grant of 60,000 nonqualified stock options at $7.00/share.
Annual meeting: James Collins, James Geraghty, Alex Sapir elected as Class II directors for 3-year term.
Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Colin Hill

Class I Director

FULC · Fulcrum Therapeutics, Inc.

Effective: 2024-06-17
Filed: June 17, 2024, 7:59 PM ET

elected Colin Hill as a member of the Board, effective June 17, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Colin Hill was elected as Class I Director at Fulcrum Therapeutics, Inc..

Action: elected
Role: Class I Director

Exact text from the filing

elected Colin Hill as a member of the Board, effective June 17, 2024

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-162653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.